相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models
Shinichi Esaki et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Sequence of a fusogenic herpes simplex virus, RH2, for oncolytic virotherapy
Gen Takahashi et al.
JOURNAL OF GENERAL VIROLOGY (2013)
A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer
A. Nakao et al.
CANCER GENE THERAPY (2011)
Virotherapy induces massive infiltration of neutrophils in a subset of tumors defined by a strong endogenous interferon response activity
X. Fu et al.
CANCER GENE THERAPY (2011)
A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma
Hiroo Takaoka et al.
VIROLOGY JOURNAL (2011)
Oncolysis Using Herpes Simplex Virus Type 1 Engineered to Express Cytosine Deaminase and a Fusogenic Glycoprotein for Head and Neck Squamous Cell Carcinoma
Daniel L. Price et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2010)
Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck
Kevin J. Harrington et al.
CLINICAL CANCER RESEARCH (2010)
The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon
Robin J. Prestwich et al.
HUMAN GENE THERAPY (2009)
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
Neil N. Senzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10
Daisuke Watanabe et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2008)
NK cells and cancer immunosurveillance
I. Waldhauer et al.
ONCOGENE (2008)
Herpes simplex virus type-I (HSV-I) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice
Anna Israyelyan et al.
VIROLOGY JOURNAL (2008)
Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model
Hongtao Li et al.
JOURNAL OF GENE MEDICINE (2007)
Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus
Yoko Ushijima et al.
MICROBES AND INFECTION (2007)
Links between innate and cognate tumor immunity
Francois Ghiringhelli et al.
CURRENT OPINION IN IMMUNOLOGY (2007)
Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma
Yasushi Fujimoto et al.
ACTA OTO-LARYNGOLOGICA (2006)
A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus
Xinping Fu et al.
MOLECULAR THERAPY (2006)
Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers
S Varghese et al.
CANCER GENE THERAPY (2006)
Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector
TD McKee et al.
CANCER RESEARCH (2006)
Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses
S Sugiura et al.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2004)
Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer
A Nakao et al.
ANNALS OF ONCOLOGY (2004)
Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity
M Nakamori et al.
MOLECULAR THERAPY (2004)
HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer
DL Thomas et al.
MOLECULAR THERAPY (2003)
Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model
CG Miller et al.
MOLECULAR THERAPY (2003)
Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice
H Takakuwa et al.
ARCHIVES OF VIROLOGY (2003)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing
T Todo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma
RJ Wong et al.
HUMAN GENE THERAPY (2001)
Enhancement of herpes simplex virus-induced polykaryocyte formation by 12-O-tetradecanoyl phorbol 13-acetate: Association with the reorganization of actin filaments and cell motility
Y Yura et al.
INTERVIROLOGY (2000)
分享论文
